APPN Jumps 26% as EPS Revisions Fuel Software Rally
Appian (APPN) led gainers with a 26.0% jump to $48.78 after its EPS growth estimate was revised upward, supported by a Citi buy rating citing AI-driven demand. Alamar Biosciences (ALMR) rose 21.4% following a 3.8pp EPS revision, while Black Rock Coffee Bar (BRCB) gained 20.6% on a 1.3pp upward revision. Real REMAX Group (REAX) surged 17.0% after a massive 99.0pp EPS estimate hike, and Agios Pharmaceuticals (AGIO) added 15.6% on a 34.9% growth estimate.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| APPN | Technology | 2026-10-13 | N/A | +26.0% |
| ALMR | Healthcare | 2026-10-14 | +3.8pp | +21.4% |
| BRCB | Consumer Cyclical | 2026-10-14 | +1.3pp | +20.6% |
| REAX | Real Estate | 2026-10-14 | +99.0pp | +17.0% |
| AGIO | Healthcare | 2026-10-15 | N/A | +15.6% |
Why did APPN stock jump in October 2026?
APPN jumped 26.0% (from $38.71 to $48.78) after analysts raised its next-year EPS growth estimate to 31.3% on October 13.
The revision, caught by our screener, was reinforced by a Citi note on October 15 that highlighted Appian's stronger execution, accelerating cloud growth, and improving federal demand for AI-powered process automation. With Q3 results due November 5, investors are betting the revised estimate undershoots actual momentum. The stock's gain reflects growing confidence in Appian's AI-driven platform amid rising enterprise demand.
APPN EPS revision history → · Screener snapshot from 2026-10-13 →
FAQ: APPN
Why did APPN stock jump?
APPN jumped 26.0% to $48.78 after its next-year EPS growth estimate was revised to 31.3% on October 13, with a Citi buy rating on October 15 adding fuel.
Is APPN a buy after the rally?
Citi maintains a buy rating on Appian, citing stronger execution and accelerating cloud growth, though the stock has already gained 26% since detection.
What is APPN's EPS growth estimate?
Appian's next-year EPS growth estimate stands at 31.3% as of October 13, 2026.
Why did ALMR stock jump in October 2026?
ALMR jumped 21.4% (from $25.37 to $30.79) after its next-year EPS growth estimate was revised upward from 45.3% to 49.1% on October 14.
The 3.8 percentage point increase signaled stronger expected profitability for the healthcare company, and the market responded with a sharp rally. No company-specific news accompanied the move, suggesting the revision itself drove buying as investors positioned for accelerated earnings growth.
ALMR EPS revision history → · Screener snapshot from 2026-10-14 →
FAQ: ALMR
Why did ALMR stock jump?
ALMR jumped 21.4% to $30.79 after its next-year EPS growth estimate was revised up from 45.3% to 49.1% on October 14.
What caused ALMR's surge?
The surge was driven by a 3.8 percentage point upward revision to ALMR's next-year EPS growth estimate, reflecting improved earnings expectations.
What is ALMR's EPS growth estimate?
ALMR's next-year EPS growth estimate is 49.1% following the October 14 revision.
Why did BRCB stock jump in October 2026?
BRCB jumped 20.6% (from $7.22 to $8.71) after its next-year EPS growth estimate was revised from 28.7% to 30.0% on October 14.
The 1.3 percentage point increase, while modest, signaled resilient earnings momentum for the coffee chain operator. With no company-specific news in the window, the rally reflects broader optimism in consumer cyclical names benefiting from stable demand and pricing power.
BRCB EPS revision history → · Screener snapshot from 2026-10-14 →
FAQ: BRCB
Why did BRCB stock jump?
BRCB jumped 20.6% to $8.71 after its next-year EPS growth estimate was revised up from 28.7% to 30.0% on October 14.
Is BRCB a buy after the rally?
The 20.6% gain since detection may prompt caution, but the upward EPS revision to 30.0% growth supports a positive earnings outlook.
What is BRCB's EPS growth estimate?
BRCB's next-year EPS growth estimate is 30.0% as of October 14, 2026.
Why did REAX stock jump in October 2026?
REAX jumped 17.0% (from $13.60 to $15.91) after its next-year EPS growth estimate was revised from 195.2% to 294.2% on October 14.
The massive 99.0 percentage point increase reflected a dramatic improvement in expected earnings, and the market responded with a strong rally. A subsequent announcement on October 19 that Real REMAX Group will host its Q3 2026 earnings call kept investor attention on the upcoming results.
REAX EPS revision history → · Screener snapshot from 2026-10-14 →
FAQ: REAX
Why did REAX stock jump?
REAX jumped 17.0% to $15.91 after its next-year EPS growth estimate was revised up from 195.2% to 294.2% on October 14.
What caused REAX's surge?
The surge was driven by a 99.0 percentage point upward revision to REAX's next-year EPS growth estimate, signaling a dramatic earnings acceleration.
What is REAX's EPS growth estimate?
REAX's next-year EPS growth estimate is 294.2% following the October 14 revision.
Why did AGIO stock jump in October 2026?
AGIO jumped 15.6% (from $32.32 to $37.36) after analysts raised its next-year EPS growth estimate to 34.9% on October 15.
The upward revision, detected by our screener, pointed to stronger expected profitability for the biopharma company. With no company-specific news in the window, the gain reflects growing confidence in Agios's earnings trajectory and sector momentum in healthcare.
AGIO EPS revision history → · Screener snapshot from 2026-10-15 →
FAQ: AGIO
Why did AGIO stock jump?
AGIO jumped 15.6% to $37.36 after its next-year EPS growth estimate was revised to 34.9% on October 15.
Is AGIO a buy after the rally?
The 15.6% gain since detection reflects improved earnings expectations, but investors should weigh the stock's recent momentum against its pipeline progress.
What is AGIO's EPS growth estimate?
AGIO's next-year EPS growth estimate is 34.9% as of October 15, 2026.
Today's broad-based rallies—led by APPN's 26% surge—signal that upward EPS revisions are being rewarded across technology, healthcare, consumer, and real estate sectors, suggesting a market environment where earnings momentum drives outperformance.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →